Giovanni Giardina

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Valentina Guarneri, Antonio Frassoldati, Alberto Bottini et al. · Journal of Clinical Oncology · 2012 · 366 citations · Full text

Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness

Melania Costantini, Paolo Belli, Pierluigi Rinaldi et al. · Clinical Radiology · 2010 · 141 citations

Engineering, Medical Imaging, Medicine +12

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature

Francesca Rovera, Matteo Lavazza, Stefano La Rosa et al. · International Journal of Surgery · 2013 · 48 citations · Full text

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Lucia Del Mastro, Francesca Poggio, Eva Blondeaux et al. · The Lancet Oncology · 2022 · 46 citations

End-of-study Results, Breast Oncology, Early-stage Breast Cancer +6